Search results (1331)
« Back to PublicationsReal-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Kuhnl A. et al, (2019), BLOOD, 134
Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common
Booth S. et al, (2019), BLOOD, 134
Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma
Shoushtari A. et al, (2019), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7
Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors
Middleton M. et al, (2019), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7
Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.
Di Genua C. et al, (2019), Haematologica, 104, 2215 - 2224
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC. et al, (2019), Gut, 68, 1918 - 1927
Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms.
Francis S. et al, (2019), Br J Haematol, 187, e69 - e72
Neurocognitive outcomes in a phase-3 randomised trial comparing adjuvant whole brain radiotherapy with observation after local treatment of brain metastases in patients with melanoma
Dhillon H. et al, (2019), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 99 - 100
Phase-3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs)
Fogarty GB. et al, (2019), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 100 - 101
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA. et al, (2019), Hematol Oncol, 37, 352 - 359
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Weber JS. et al, (2019), ANNALS OF ONCOLOGY, 30, 533 - +
Early peripheral T-cell responses predict oncological outcome to checkpoint immune blockade in metastatic melanoma
Fairfax B. et al, (2019), ANNALS OF ONCOLOGY, 30
Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study
Middleton MR. et al, (2019), ANNALS OF ONCOLOGY, 30
Identification of transcriptomic markers predictive of clonal response to checkpoint inhibitor treatment
Watson RA. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 1744 - 1745
Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Dalle S. et al, (2019), ANNALS OF ONCOLOGY, 30
Meaningfulness of HM-PRO scores: translating the science of PROs into practice
Goswami P. et al, (2019), QUALITY OF LIFE RESEARCH, 28, S84 - S85
Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis
Sasson SC. et al, (2019), ANNALS OF ONCOLOGY, 30, 530 - 530
Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application.
Lightbody G. et al, (2019), Brief Bioinform, 20, 1795 - 1811